US 11,685,727 B2Granted

Compounds active towards nuclear receptors

AssigneeNuevolution A/S

InventorsSanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana

Life of this patent

Estimating the term…

Abstract

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

Claims16

Dependent claims

A compound, stereoisomer, or salt having a structure selected from the group consisting of:

Dependencies are inferred from the claim text.

Facts

Application: 17/126,182Filed 18 Dec 2020 · us provisional application
Priority: 20 Dec 2019
Published: US 2021/0188807 A124 Jun 2021
Granted: 27 Jun 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
C07D 401/12
Containing two hetero rings: linked by a chain containing hetero atoms as chain links
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis
A61P 21/00
Drugs for disorders of the muscular or neuromuscular system

Family

Application62/951,221Us provisional application · filed 20 Dec 2019
Application63/064,502Us provisional application · filed 12 Aug 2020
US 2021/0188807 A1Pre-grant publication · published 24 Jun 2021
US 11,685,727 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results